CSL Ltd. subsidiary CSL Seqirus signed a licensing and development deal with Arcturus Therapeutics Inc. to in-license Arcturus’ late-stage self-amplifying mRNA vaccine platform technology. Arcturus will receive $200 million up front and is eligible to receive more than $1.3 billion in development milestones and over $3 billion in commercial milestones. In addition, it could capture a 40% net profit share for COVID-19 vaccines and up to double-digit royalties for vaccines against flu, pandemic preparedness and three other respiratory pathogens.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Apex, Astrazeneca, Aulos, Brim, Karyopharm, Moderna, Rhythm, Shanghai Henlius, Stealth.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akston, Biothera, Cingulate, Denali, Dragonfly, Ensysce, Harmony, Hoth, Merck, Monte Rosa, Orum, Pfizer, Pieris, Promore, Receptor, Remegen, Stealth, Teon, Unity, Xeris.

Epivax Inc. is taking part in a new project with Intravacc BV, funded by CEPI (Coalition for...

While elderly people are at a significantly higher risk of developing severe and lethal forms of...

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aim, Coeptis, Cytosorbents, Epivax, Intravacc, Intrinsix.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avrobio, Diamedica, Dyadic International, ITM Isotope Technologies München, Myeloid, Novo Nordisk, Reveragen, Santhera, Simcere.

Pfizer Inc. has divulged 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Novacyt, Radiaction, Transit Scientific.